	US 12,186,316 B2
	Pharmaceutical compositions
Zeren Wang, Shenzhen (CN); Shun Chen, Shenzhen (CN); Jiqian Peng, Shenzhen (CN); Longwei Sun, Shenzhen (CN); and Yanxin Zhao, Shenzhen (CN)
Assigned to Shenzhen Pharmacin Co., Ltd., Shenzhen (CN)
Filed by Shenzhen Pharmacin Co., Ltd., Shenzhen (CN)
Filed on Mar. 19, 2024, as Appl. No. 18/609,790.
Application 18/609,790 is a division of application No. 18/191,637, filed on Mar. 28, 2023.
Application 18/191,637 is a continuation of application No. PCT/CN2021/121695, filed on Sep. 29, 2021.
Claims priority of application No. PCT/CN2020/118608 (WO), filed on Sep. 29, 2020.
Prior Publication US 2024/0226102 A1, Jul. 11, 2024
Int. Cl. A61K 31/506 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/205 (2013.01); A61K 9/2054 (2013.01); A61K 9/4825 (2013.01); A61K 9/4866 (2013.01)]

30 Claims

1. A pharmaceutical composition, wherein the pharmaceutical composition comprises:

a) an amorphous solid dispersion that comprises:

i) nilotinib free base or a hydrochloride salt thereof, wherein the nilotinib free base or a hydrochloride salt thereof is present in the amorphous solid dispersion in an amount of about 10% to about 30% by weight;

ii) a surfactant, wherein the surfactant comprises a phospholipid, and wherein the surfactant is present in the amorphous solid dispersion in an amount of about 5% to about 50% by weight;

iii) a hydrophilic polymer, wherein the hydrophilic polymer is present in the amorphous solid dispersion in an amount of about 20% to about 80% by weight; and

iv) silicon dioxide, wherein the silicon dioxide is present in the amorphous solid dispersion in an amount of about 0.1% to about 40% by weight; wherein i, ii, iii, and iv are combined and present together prior to removing all or partial solvent to form the amorphous solid dispersion; and

b) a pharmaceutically acceptable carrier or excipient.